Benjamin L. Oakes
Co-Founder, President, CEO & ChairmanDr. Benjamin L. Oakes, Ph.D., Co-Founded Scribe Therapeutics Inc in June 2017 and its President, Chief Executive Officer and Director since June 2017. He also served as its Chief Financial Officer until March 2022. Previously, as an Innovative Genomics Institute Entrepreneurial Fellow, he focused on the holistic engineering of genome editing technologies to build novel genome editing molecules. He has contributed to over 25 publications and patent applications on topics including synthetic biology, molecular engineering, CRISPR and zinc finger-based genetic modification. He received a Ph.D. in Molecular and Cellular Biology from UC Berkeley in 2017, where he worked in the Doudna Lab and Savage Lab developing CRISPR-Cas9 molecules with enhanced characteristics. Prior to his Ph.D. he received his B.A. in the fields of Philosophy and Neurobiology from Colby College and worked as a researcher applying unbiased, combinatorial evolution methods to build tens of thousands of “version one” genome editing tools, providing an open-source framework for scientists and medical professionals to modify the genome B.C. — before the discovery of CRISPR technology.
Positions
- Company NameScribe Therapeutics Inc.Stock CodeSCTXPositionCo-Founder, President, CEO & ChairmanColleagues
- DLDavid L. ParrotCFO & Treasurer
- SLSvetlana LucasChief Operating Officer
- JAJennifer A. DoudnaCo-Founder & Scientific Advisor
- BTBrett T. StaahlCo-Founder & VP of External Innovation
- JDJames Dean WatsonIndependent Director
- JBJoshua BleharskiLead Independent Director
- BABehzad AghazadehIndependent Director
- CLCarl Lee GordonIndependent Director
